Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
about
Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in KoreaManagement of the adverse effects of lenalidomide in multiple myeloma.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaA multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trialBendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Total cost comparison in relapsed/refractory multiple myeloma.Lenalidomide in multiple myeloma-a practice guideline.Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trialLenalidomide in multiple myeloma: current role and future directions.The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.Guidelines for the diagnosis and management of multiple myeloma 2011.Managing multiple myeloma in the elderly: are we making progress?Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma.Lenalidomide in multiple myeloma: Current status and future potential.Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisationClinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients.An update on the use of lenalidomide for the treatment of multiple myeloma.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.American society of hematology.Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide.Trial Watch: Lenalidomide-based immunochemotherapy.Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.Lenalidomide in multiple myeloma.Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells.Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
P2860
Q26992002-10D92C96-7C8F-463C-96A3-13EAE466EE60Q33394632-51AFCDE3-0ADF-4483-899B-7349D7356FF0Q33403183-195014FC-73F9-4536-AEC4-93ED87ACC21CQ33404007-3A2F6EFB-5AA1-4ABE-8576-9415F56AD7F6Q33408056-5D2B9825-C250-4945-ADB6-8474C7B285C2Q33408494-6A2D3956-AF10-4263-AEE8-E32D80F3F55BQ33437691-375BE514-AB41-4E8C-BC54-470DF6F60DB2Q34088340-62A3BE00-9C60-471C-8B0B-BF5352973030Q34656086-4DA566A3-346A-470A-85D4-7DBACAF8DCBBQ36065299-333418A9-7B9A-4DFD-9B14-EF33DBC28E57Q36109802-1FF71890-5A4A-4232-B8F3-52AA58BF55AFQ36138646-53758794-9148-4FA4-B3EC-E2E5643E69C2Q37704401-8A36EF3F-4F21-49FA-859C-0C82CEFF29F1Q37800884-2E24358F-E4F9-4355-88B0-E20E2CCB6EBCQ37835695-E91FFFD9-3FAD-4EC2-83A9-86D3C3E53707Q37858523-9C07B64A-E6F9-4BE6-9BF4-0F8308BC2F23Q37862262-68FA4907-E909-4627-A9D5-675D4A2179C1Q37875193-45ED7345-0DCC-4D04-818D-2319BACBEFD1Q37888716-11166C10-70AE-445F-9FEF-0D9582E0696CQ37949201-6AE54A03-9D25-428E-BB84-7C8154EF288CQ37976672-0DBC7592-88F5-4CF5-8390-BEC1FEF8A9CEQ38013995-015E4E36-807B-4837-9B6B-A37F982B7D99Q38031989-DB28002D-8208-4245-8501-31BF6B78ED8AQ38271032-7BA6AF64-8BE8-4AF3-A2D1-40A8170EFFBFQ38446990-D56003B3-84A4-45FD-98A2-AB60031FFC84Q38462720-54361D1A-E454-4E9D-BE03-DC1EF801F10EQ38496485-A5D5DCF3-8B7E-486B-B0B9-F094CBB1F9DDQ38530066-9EF58A26-7198-49DC-86D0-C9610D843C41Q38545607-5EBDFC6A-7DB4-4F98-A087-F31083B636FBQ38672091-7659E4C9-0059-4DA0-9FCF-337822172653Q38749573-F5C4B7E3-2A3E-4A01-95A8-598011AA7A08Q39524467-C057010C-3B11-4151-9A63-9F03090E942AQ39890742-AC5C791A-3724-42AB-A565-43505FC1F956Q41602673-6CCB3782-F5C6-42E5-98C6-3BFA3FBCA21AQ41655429-57075056-5162-4692-ABD1-84FB5A7509B7Q42737828-161A15E5-FEFF-4611-8E4C-9BA113D04937Q43195076-9AA673CA-72D6-48CC-B761-1A7B62C0E496Q43247044-8D6C0983-5517-4470-8D28-E850A7EE4534Q43269070-4BE427EE-706F-4919-892B-6DA0C4EA56DFQ43726973-F0FA796B-128A-4353-A2DF-F9960C86A19C
P2860
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lenalidomide in combination wi ...... r refractory multiple myeloma.
@en
Lenalidomide in combination wi ...... r refractory multiple myeloma.
@nl
type
label
Lenalidomide in combination wi ...... r refractory multiple myeloma.
@en
Lenalidomide in combination wi ...... r refractory multiple myeloma.
@nl
prefLabel
Lenalidomide in combination wi ...... r refractory multiple myeloma.
@en
Lenalidomide in combination wi ...... r refractory multiple myeloma.
@nl
P2093
P2860
P50
P1476
Lenalidomide in combination wi ...... or refractory multiple myeloma
@en
P2093
Andrew Belch
Donna M Weber
Edward A Stadtmauer
Jerome B Zeldis
Marta Olesnyckyj
Miles H Prince
Robert D Knight
Zhinuan Yu
P2860
P304
P356
10.1111/J.1600-0609.2009.01257.X
P577
2009-03-19T00:00:00Z